151 related articles for article (PubMed ID: 11303433)
21. Ensuring safe and effective medications for children.
Budetti PP
JAMA; 2003 Aug; 290(7):950-1. PubMed ID: 12928474
[No Abstract] [Full Text] [Related]
22. OTCs under review: an update on what's in and what's out.
Welsh JS
Am Pharm; 1980 Sep; NS20(9):11-5. PubMed ID: 7424784
[No Abstract] [Full Text] [Related]
23. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
24. Drug development process for a product with a primary pediatric indication.
Allen AJ; Michelson D
J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
[TBL] [Abstract][Full Text] [Related]
25. New (still proposed) rules for sunscreen. UVA testing and ranking may be the most important change.
Harv Health Lett; 2010 Jun; 35(8):6. PubMed ID: 20700956
[No Abstract] [Full Text] [Related]
26. FDA draft guidelines for the clinical evaluation of antiinflammatory and antirheumatic drugs in children. Executive summary.
Giannini EH; Lovell DJ; Hepburn B
Arthritis Rheum; 1995 May; 38(5):715-8. PubMed ID: 7748227
[No Abstract] [Full Text] [Related]
27. Therapeutic orphans: who speaks for children?
Shirkey HC
South Med J; 1970 Nov; 63(11):1361-3. PubMed ID: 5475304
[No Abstract] [Full Text] [Related]
28. Off label use of antimicrobial agents in infants, children and adolescents: a time for action.
Abramson JS; Holland ME
Pediatr Infect Dis J; 1998 Aug; 17(8):739-44. PubMed ID: 9726350
[No Abstract] [Full Text] [Related]
29. What the paediatricians need--the launch of paediatric research in Europe.
Ramet J
Eur J Pediatr; 2005 May; 164(5):263-5. PubMed ID: 15726409
[TBL] [Abstract][Full Text] [Related]
30. Pediatric pharmacology: the path clears for a noble mission.
Wilson JT
J Clin Pharmacol; 1993 Mar; 33(3):210-2. PubMed ID: 8463433
[TBL] [Abstract][Full Text] [Related]
31. The march toward rational therapeutics in children.
Gorman RL
Pediatr Infect Dis J; 2003 Dec; 22(12):1119-23. PubMed ID: 14688584
[TBL] [Abstract][Full Text] [Related]
32. FDA to require pediatric studies for drugs commonly used in children.
Miller JL
Am J Health Syst Pharm; 1999 Feb; 56(3):203. PubMed ID: 10030499
[No Abstract] [Full Text] [Related]
33. Labeling changes for Viramune.
AIDS Patient Care STDS; 2008 Jul; 22(7):604-5. PubMed ID: 18661593
[No Abstract] [Full Text] [Related]
34. Efficacy of labeling of foods and pharmaceuticals.
Viscusi WK
Annu Rev Public Health; 1994; 15():325-43. PubMed ID: 8054088
[No Abstract] [Full Text] [Related]
35. FDA proposes more stringent pediatric-use labeling of prescription drug products.
Am J Hosp Pharm; 1993 Jan; 50(1):13, 16. PubMed ID: 8427271
[No Abstract] [Full Text] [Related]
36. Paediatric labelling requirements. Implications for pharmacokinetic studies.
Wilson JT; Kearns GL; Murphy D; Yaffe SJ
Clin Pharmacokinet; 1994 Apr; 26(4):308-25. PubMed ID: 8013163
[TBL] [Abstract][Full Text] [Related]
37. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
38. How the FDA determines the "safety" of drugs: are drugs used in obstetrics really safe?
Haire D
J Nurse Midwifery; 1982; 27(2):28-32. PubMed ID: 6917884
[No Abstract] [Full Text] [Related]
39. Just a spoonful of sugar: drug safety for pediatric populations.
Noah BA
J Law Med Ethics; 2009; 37(2):280-91. PubMed ID: 19493073
[TBL] [Abstract][Full Text] [Related]
40. The federal preemption debate in pharmaceutical labeling product liability actions.
Gross JM; Curry JA
Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
